The Body Composition Problem in GLP-1 Research
GLP-1 receptor agonist drugs produce substantial weight loss — that much is well established. What is becoming increasingly important in the research community is a more granular question: what exactly is being lost? Total weight is a relatively crude endpoint. The clinically meaningful distinction is between fat mass loss (which is the therapeutic goal) and lean mass loss (which is not, and which carries consequences for physical function, metabolic rate, and long-term health).
DXA (dual-energy X-ray absorptiometry) sub-studies embedded within the major GLP-1 trials are providing increasingly detailed body composition data that is complicating the simple "weight lost is good" narrative, particularly in populations where lean mass preservation matters most.
What the DXA Data Currently Shows
The STEP-1 semaglutide trial DXA sub-study reported approximately 38% of total weight lost as lean mass. For a participant losing 15 kg on semaglutide, this translates to roughly 5.7 kg of lean mass lost — including skeletal muscle. The SURMOUNT-1 tirzepatide DXA data was somewhat more favourable, reporting approximately 30% lean mass loss — still substantial at scale.
For context, intentional caloric restriction without exercise typically produces 30–40% lean mass loss — so GLP-1 drugs perform comparably to dietary restriction alone on this measure. This underlines that the lean mass loss is primarily a consequence of the caloric deficit rather than a direct pharmacological effect of GLP-1 receptor activation.
| Compound | Trial | Total Weight Loss | Lean Mass % |
|---|---|---|---|
| Semaglutide | STEP-1 DXA sub-study | ~15% at 68 weeks | ~38% |
| Tirzepatide | SURMOUNT-1 DXA | ~22.5% at 72 weeks | ~30% |
| Retatrutide | Phase 3 TRIUMPH (pending) | Phase 2: 24.2% at 48 wks | DXA sub-study ongoing |
| Diet only (ref) | Meta-analysis | ~8–10% | ~35–40% |
| Diet + resistance | Exercise studies | ~8–10% | ~10–20% |
Research Perspective
The lean mass question is particularly significant for the elderly and sarcopenic populations where GLP-1 use is expanding. A 5 kg lean mass loss in a 70-year-old with already-reduced muscle mass has very different consequences than the same loss in a well-muscled 35-year-old. Age-stratified body composition sub-analyses are an important research gap.
Four Research Approaches to Lean Mass Preservation
Resistance Training
Small studies combining GLP-1 drugs with structured resistance training show approximately 2× lean mass retention vs no-exercise groups for similar total weight loss. The minimum effective exercise dose isn't well characterised yet.
Protein Intake Optimisation
Higher protein intakes (1.6–2.0 g/kg/day) during GLP-1 treatment reduce the proportion of weight lost as lean mass in general caloric restriction studies. GLP-1 trial populations consuming higher protein show better lean/fat ratios.
GHRH Analogue Co-administration
Tesamorelin (GHRH analogue) stimulates GH/IGF-1 axis anabolic signalling, which promotes lean mass preservation. No published clinical combination data with GLP-1 drugs exists yet — a significant research gap.
Myostatin Inhibition Research
Myostatin (GDF-8) negatively regulates muscle mass. Compounds inhibiting myostatin signalling during GLP-1 treatment are a theoretical strategy for preserving lean mass. Currently purely preclinical.
Research compound · For scientific use only
Tesamorelin
GHRH analogue · ≥99% HPLC purity · Lyophilised
- GH/IGF-1 axis stimulation
- Lean mass preservation research
- Metabolic research
The Retatrutide Hypothesis: Does Glucagon Help?
One of the most important open questions for retatrutide's triple agonist profile is whether glucagon receptor activation produces a more favourable fat-to-lean mass ratio compared to GLP-1 monoagonism. The hypothesis: glucagon receptor activation preferentially promotes hepatic and adipose fatty acid oxidation, directing metabolic fuel sourcing specifically toward fat. If this means more of the caloric deficit is met from fat stores rather than lean tissue catabolism, the lean mass proportion of weight loss could be lower than with GLP-1 compounds alone.
The TRIUMPH DXA sub-studies are the designed instrument to answer this question, and their results — comparing retatrutide to semaglutide controls with matched weight loss — will be among the most scientifically significant body composition publications in the field when released. For researchers studying metabolic peptide compounds, this is an active frontier.
Research Use Only
Research peptides including retatrutide and tesamorelin are for in vitro and preclinical laboratory use only. They are not approved for human use and not intended for human administration.